Representative engagement

Sizing Biologics Contract Manufacturing Capacity by Format and Scale

A multi expert panel putting plant operators and drug sponsors in one session

The challenge

The consensus on tight capacity fell apart under pressure

A consulting case team was sizing the market for biologics contract manufacturing, the plants that make biological medicines for the companies that own them. Published commentary agreed that capacity was tight. That agreement was the least reliable part of the picture. Capacity in biologics is not one number: it depends on the format being made, the scale of the run, and how much of a plant is already committed to long running programs.

Treating capacity as one pool produces a headline the client cannot act on, and the published announcements only reproduce the consensus. Testing it needs the plant side and the sponsor side in one conversation. Plants describe what they can run; sponsors describe what they can book. The gap between those accounts is the finding.

The Nextyn approach

We put the plants and the sponsors in one session

We convened a panel that spanned both sides of the market: former plant leads who had run the manufacturing, supply chain heads at the sponsor companies who book the slots, and business development directors who negotiate them. The brief asked for seats that would see the same question differently, because a panel of people who agree produces confidence rather than information.

The session was chaired so the disagreement became explicit in the room, rather than being averaged away in a write up. Coverage spanned the different formats and scales instead of treating capacity as one pool. Because participants hear each other in this format, everyone was cleared through our compliance checks before the session was scheduled.

The outcome

The constraint was located rather than simply asserted

The panel moved the answer from a general claim about tightness to a specific account of which formats and scales were constrained and which were not. That held when the client challenged it, which a study built on announced expansions would not have. The team delivered a market size the client could act on.

The panel also shortened the work. Reconciling the same disagreement across separate calls would have taken another round of sourcing, and the case timetable had no room for it.

Related reading

More on sizing a market around a real constraint

Writing from the Nextyn desk.

Start here

Speak to an expert about your question

A dedicated Client Solutions Manager will be in touch shortly to help with your research needs.

Request life sciences experts

Tell us about your research needs

Start with a single project. We shape the commercial terms around how you want to work.

We use these details to route your brief. No newsletter, no list.

Cookies

We measure how this site is used so we can improve it. You can turn that off at any time, and we will not use anything for advertising unless you allow it.